Merck Acquires Bio-Techne for Near-Term Cash Value

Bio-Techne shareholders have approved the Agreement and Plan of Merger under which Merck KGaA will acquire the company. The deal follows the expiration of the U.S. antitrust waiting period on September 18, 2026.

The merger proposal passed by a wide margin at a special meeting where 78.55% of eligible shares were represented. Bio-Techne's shareholders will receive near-term cash value as a result of the acquisition.

Merk KGaA's acquisition of Bio-Techne is expected to close by late 2026 or early 2027, subject to remaining regulatory approvals. The deal will turn Bio-Techne into a wholly owned Merck subsidiary and expand Merck's presence across life science workflows from discovery through commercial manufacturing.